Ukraine to introduce reference pricing and plans for prescription system

1 May 2012

The Ukraine Ministry of Health and domestic producers of pharmaceuticals have signed a memorandum of understanding to regulate the prices of hypertension and diabetes drugs, reports Sebastian Gensior, writing on the europe-health-care-eu web site.

The pilot project will begin as of June 1 and there will be a price stop on hypertension drugs. Patients suffering from hypertension can also receive discounts on drugs if they show a prescription from a doctor.

Another reform will have a more profound impact on the Ukrainian pharmaceutical market, says Mr Gensior. So far, no prescription is needed to purchase any drug in Ukraine. The government wants to tackle this law and plans to introduce prescriptions for medicines. According to local experts, 85% of the population buys its drugs without prescription and mainly based on the advice of friends, or advertising.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics